In the two decades since the discovery of the nociceptin opioid receptor (NOP) and its
ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been achieved in …

Despite high sequence similarity between NOP (nociceptin/orphanin FQ opioid peptide) and
opioid receptors, marked differences in endogenous ligand selectivity, signal transduction …

Up to 60% of inflammatory bowel disease (IBD) patients experience abdominal pain in their
lifetime regardless of disease activity. Pain negatively affects different areas of daily life and …

This paper is the thirty-seventh consecutive installment of the annual review of research
concerning the endogenous opioid system. It summarizes papers published during 2014 …

Inflammatory bowel diseases (IBD) are chronic, relapsing disorders affecting gastrointestinal
(GI) tract and associated with intestinal mucosa damage and inflammation. The principal …

Introduction Visceral pain is a symptom reported by over 70% of inflammatory bowel disease
(IBD) sufferers. So far, a single, specific cause of this debilitating state has not been …

One of the main challenges in contemporary medicinal chemistry is the development of safer
analgesics, used in the treatment of pain. Currently, moderate to severe pain is still treated …

In our society today, pain has become a main source of strain on most individuals. It is
crucial to develop novel treatments against pain while focusing on decreasing their adverse …

Two decades have passed since the peptide, nociceptin/orphanin FQ (N/OFQ), and its
cognate (NOP) receptor were discovered. Although NOP receptor activation causes a similar …

As clinical use of currently available opioid analgesics is often impeded by dose-limiting
adverse effects, such as abuse liability and respiratory depression, new approaches have …